Revance Therapeutics (RVNC) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Revance Reports First Quarter 2021 Financial Results, Provides Corporate Update
May 10, 2021 4:05 PM EDT- Q1 revenue for the RHA® Collection of dermal fillers of $11.6 million
- HintMDs processing volume run-rate more than doubled to over $400 million from the prior quarter
- Over 1,500 aesthetic accounts activated across products and services at quarter-end
- Status of the U.S. Food and Drug Administration (FDA) pre-approval inspection
- Conference call and webcast today at 4:30 p.m. ET
NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial... More
